GLP-1 Drug Shows Promise in Slowing Aging and Extending Lifespan in Mice

What's new

A recent study funded by the National Institutes of Health (NIH) has explored the potential of GLP-1 receptor agonists, specifically semaglutide, to influence the aging process. Researchers found that treating older female mice with semaglutide not only improved various age-related physiological functions but also extended their lifespan. This investigation compared the effects of the GLP-1 drug with those of calorie restriction, a known lifespan-extending intervention, revealing that while both slowed aging, they did so through different biological pathways [1].

The science behind it

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that plays a role in regulating blood sugar and appetite. GLP-1 drugs, which mimic this hormone, are commonly used to manage conditions like type 2 diabetes and obesity. Beyond their primary effects, these drugs have been observed to offer other benefits, such as reducing risks for cardiovascular, kidney, liver, and neurodegenerative diseases, some of which are not fully explained by weight loss or improved blood sugar control alone [1].

The research team, led by Dr. Danica Chen at the University of California, Berkeley, administered semaglutide daily to 20-month-old female mice for three months. Compared to control groups, the treated mice demonstrated enhanced muscular and cognitive function, better coordination, balance, and endurance. The drug also reversed age-related changes in gene activity. Furthermore, mice treated with semaglutide from 20 months until their natural death lived approximately 100 days longer than untreated mice [1].

To understand if these benefits were solely due to reduced calorie intake, the scientists compared semaglutide treatment with a 24% calorie-restricted diet in another group of 20-month-old female mice over five months. Both interventions prevented declines in age-associated physiological functions. However, semaglutide uniquely improved specific functions like exploratory behavior, spatial memory, and glucose tolerance. Interestingly, while calorie restriction slowed down daytime energy usage, the GLP-1 group's energy usage remained unchanged, suggesting distinct underlying mechanisms for their anti-aging effects [1].

What it means in practice

The findings suggest that GLP-1 drugs might offer a novel approach to addressing age-related decline, potentially independent of their well-known effects on weight and blood sugar. If these anti-aging effects translate to humans, GLP-1 agonists could have broad implications for mitigating a wide range of chronic diseases that are deeply intertwined with the aging process. The distinction in mechanisms between GLP-1 drugs and calorie restriction also opens up new avenues for research into the complex biology of aging and potential combination therapies [1].

Caveats

It is crucial to note that this research was conducted in mice, and results from animal studies do not always directly translate to humans. While mice possess the same GLP-1 receptor targeted by semaglutide, further extensive research is necessary to confirm these findings in human populations before any clinical applications related to aging can be considered. Dr. Rafael de Cabo, a senior investigator at NIH’s National Institute on Aging (NIA), emphasized that while the potential is significant, more research is needed to draw firm conclusions regarding human applicability [1].

Source: [1] https://www.nih.gov/news-events/nih-research-matters/glp-1-drug-slows-aging-mice